Evolution of Technologies for Therapeutic Antibodies-from Mabs to Biosimilars

Bharat Book Bureau provides the report, on “Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars”. The report answers key questions that are paramount for understanding the technologies involved in the production of therapeutic antibodies. (https://www.bharatbook.com/healthcare-market-research-reports-686697/evolution-technologies-therapeutic-antibodies-biosimilars.html)

July 15th, 2015- Mumbai, India: Bharatbook.com announces a report on “Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars”. This report will help stakeholders to understand prevailing technologies and their merits and limitations.

The scope of the report is to highlight and gauge existing technologies in the production of therapeutic mAbs (https://www.bharatbook.com/healthcare-market-research-reports-686697/evolution-technologies-therapeutic-antibodies-biosimilars.html). The report also discusses key insights on interchangeability and substitution of therapeutic antibodies and biosimilars.

Further, there is also an assessment of the current drivers and restraints that affect the uptake of biosimilars.

The report answers key questions that are paramount for understanding the technologies involved in the production of therapeutic antibodies, such as:

• What are the various types of monoclonal therapeutic antibodies?

• Why is there a need for alternate forms of therapeutic antibodies?

• What is the likely future direction for research in the development and manufacture of monoclonal antibodies?

• What are the key features of a genetically modified mouse for antibody production?

• How do ethical concerns drive the direction of research of future monoclonal antibodies?

• What are the crucial features in establishing biosimilarity?

• Is interchangeability between innovator monoclonal antibodies and biosimilars ever achievable?

• What are the limitations in the technologies used to evaluate the extents of biosimilarity?

• Who are the...